ClinicalTrials.gg
CompletedNCT03230487Updated Nov 28, 2025Results posted

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

A Phase 1 interventional study of Placebo Single Dose (SD) and BI 1015550 Single Dose (SD) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Part 1 (SRD (Single-rising dose)):

The primary objective of this trial part is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of single rising doses.

Secondary objectives are the exploration of the pharmacokinetics of BI 1015550 after single dosing.

Part 2 (MRD (Multiple-rising dose)):

In Part 2, the primary objective is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of multiple rising doses.

Secondary objectives are the exploration of the pharmacokinetics of BI 1015550 after multiple dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs, 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 45 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including vital signs or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 55 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders, including but not limited to mood disorders and any history of suicidality.
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (consumption of more than 20 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two months after the study completion. Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two months)

In addition, the following trial-specific exclusion criteria apply:

  • Positive or missing fecal occult blood (no retest allowed),
  • Positive testing for fecal calprotectin (retest allowed)
  • Positive testing for hematuria if confirmed by microscopic urine analysis (retest allowed)
  • Any lifetime history of suicidal behavior (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)
  • Any suicidal ideation (i.e. type 1-5) on the Columbia Suicidal Severity Rating (C-SSRS) in the past 12 months (i.e.passive/active suicidal thought, active suicidal thought with method, active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent) (only Part 2)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
42 participants (actual)

Study arms

  • Placebo comparator
    Placebo Single Dose (SD)

    Subjects received single dose of placebo tablet matching to BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1

    Drug: Placebo Single Dose (SD)

  • Placebo comparator
    Placebo Multiple Dose (MD)

    Subjects received placebo tablet matching to BI 1015550 twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14

    Drug: Placebo Multiple Dose (MD)

  • Experimental
    BI 1015550 36 milligram (mg) Single Dose (SD)

    Subjects received single dose of BI 1015550 36 mg (6 tablets of 6 mg) orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1

    Drug: BI 1015550 Single Dose (SD)

  • Experimental
    BI 1015550 48 milligram (mg) Single Dose (SD)

    Subjects received single dose of BI 1015550 48 mg (8 tablets of 6 mg) orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1

    Drug: BI 1015550 Single Dose (SD)

  • Experimental
    BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)

    Subjects received BI 1015550 6 mg (1 tablet of 6 mg) twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14

    Drug: BI 1015550 Multiple Dose (MD)

  • Experimental
    BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)

    Subjects received BI 1015550 12 mg (2 tablets of 6 mg) twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14

    Drug: BI 1015550 Multiple Dose (MD)

Interventions

  • DrugPlacebo Single Dose (SD)

    Subjects received single dose of placebo tablet matching to BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours

  • Subjects received single dose of BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours

    Also known as: Nerandomilast, JASCAYD®

  • DrugPlacebo Multiple Dose (MD)

    Subjects received placebo tablet matching to BI 1015550 twice daily (bid) orally with 240 milligram (mL) of water after a moderate fat meal.

  • Subjects received BI 1015550 twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal.

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Drug-related Adverse Events (AEs)

    Number of subjects with drug-related Adverse Events (AEs).

    Time frame: For SRD: From the administration of study medication until 7 days, up to day 8. For MRD: From the first administration of study medication until 7 days after the last administration of study medication, i.e. up to 21 days after first drug administration.

Secondary outcomes

  1. Part 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Part 1 (SRD): Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

    Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration

  2. Part 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

    Part 1 (SRD): Maximum measured concentration of the BI 1015550 in plasma (Cmax).

    Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration

  3. Part 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1)

    Part 2 (MRD) - After the first dose : Area under the concentration-time curve of the BI 1015550 in plasma over a uniform dosing interval tau after administration of the first dose (AUCτ,1).

    Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration

  4. Part 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

    Part 2 (MRD) - After the first dose : Maximum measured concentration of the BI 1015550 in plasma (Cmax).

    Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration

  5. Part 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)

    Part 2 (MRD) - After the last dose: Area under the concentration-time curve of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (AUCtau,ss).

    Time frame: Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 311:55, 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00

  6. Part 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss)

    Part 2 (MRD) - After the last dose: Maximum measured concentration of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (Cmax,ss).

    Time frame: Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00

  7. Part 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax)

    Part 2 (MRD) - Accumulation ratio based on Cmax,ss (RA,Cmax). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00.

    Time frame: Up to 504 hours following first drug administration, Please find the time frame in description section.

  8. Part 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC)

    Part 2 (MRD) - Accumulation ratio based on AUC0-tau (RA,AUC). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00.

    Time frame: Up to 324 hours following first drug administration, Please find the time frame in description section.

07

Results

Posted Nov 28, 2025

Participant flow

Safety, tolerability, and pharmacokinetics of BI 1015550 in healthy male subjects. Single rising dose (SRD) part: Partially randomized within dose groups, placebo-controlled, single-blind, parallel-group design; Multiple rising dose (MRD) part: Partially randomized within dose groups, placebo-controlled, double-blind, parallel-group design.

Participant flow — Overall Study
MilestonePlacebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 milligram (mg) Single Dose (SD)BI 1015550 48 milligram (mg) Single Dose (SD)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Started686688
Completed686588
Not completed000100
Withdrew: Adverse event000100

Outcome measures

PrimaryNumber of Subjects With Drug-related Adverse Events (AEs)

Number of subjects with drug-related Adverse Events (AEs).

Time frame:
For SRD: From the administration of study medication until 7 days, up to day 8. For MRD: From the first administration of study medication until 7 days after the last administration of study medication, i.e. up to 21 days after first drug administration.
Reported as:
Count of participants · Participants
Number of Subjects With Drug-related Adverse Events (AEs)
ParticipantsPlacebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 milligram (mg) Single Dose (SD)BI 1015550 48 milligram (mg) Single Dose (SD)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Number of Subjects With Drug-related Adverse Events (AEs)112424
SecondaryPart 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Part 1 (SRD): Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

Time frame:
Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration
Reported as:
Geometric mean · nanomole*hour/liter (nmol∙h/L)
Part 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nanomole*hour/liter (nmol∙h/L)BI 1015550 36 milligram (mg) Single Dose (SD)BI 1015550 48 milligram (mg) Single Dose (SD)
Part 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)5910 ± 21.28700 ± 17.2
SecondaryPart 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

Part 1 (SRD): Maximum measured concentration of the BI 1015550 in plasma (Cmax).

Time frame:
Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration
Reported as:
Geometric mean · nanomole/liter (nmol/L)
Part 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)
nanomole/liter (nmol/L)BI 1015550 36 milligram (mg) Single Dose (SD)BI 1015550 48 milligram (mg) Single Dose (SD)
Part 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)710 ± 20.7955 ± 15.5
SecondaryPart 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1)

Part 2 (MRD) - After the first dose : Area under the concentration-time curve of the BI 1015550 in plasma over a uniform dosing interval tau after administration of the first dose (AUCτ,1).

Time frame:
Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration
Reported as:
Geometric mean · nanomole*hour/liter (nmol∙h/L)
Part 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1)
nanomole*hour/liter (nmol∙h/L)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1)564 ± 24.81370 ± 15.9
SecondaryPart 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)

Part 2 (MRD) - After the first dose : Maximum measured concentration of the BI 1015550 in plasma (Cmax).

Time frame:
Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration
Reported as:
Geometric mean · nanomole/liter (nmol/L)
Part 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)
nanomole/liter (nmol/L)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)103 ± 28.2229 ± 29.9
SecondaryPart 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)

Part 2 (MRD) - After the last dose: Area under the concentration-time curve of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (AUCtau,ss).

Time frame:
Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 311:55, 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00
Reported as:
Geometric mean · nanomole*hour/liter (nmol∙h/L)
Part 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)
nanomole*hour/liter (nmol∙h/L)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)1050 ± 25.72300 ± 15.8
SecondaryPart 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss)

Part 2 (MRD) - After the last dose: Maximum measured concentration of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (Cmax,ss).

Time frame:
Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00
Reported as:
Geometric mean · nanomole/liter (nmol/L)
Part 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss)
nanomole/liter (nmol/L)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss)164 ± 21.3348 ± 14.1
SecondaryPart 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax)

Part 2 (MRD) - Accumulation ratio based on Cmax,ss (RA,Cmax). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00.

Time frame:
Up to 504 hours following first drug administration, Please find the time frame in description section.
Reported as:
Geometric mean · Ratio
Part 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax)
RatioBI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax)1.60 ± 35.01.52 ± 23.6
SecondaryPart 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC)

Part 2 (MRD) - Accumulation ratio based on AUC0-tau (RA,AUC). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00.

Time frame:
Up to 324 hours following first drug administration, Please find the time frame in description section.
Reported as:
Geometric mean · Ratio
Part 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC)
RatioBI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
Part 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC)1.85 ± 9.911.68 ± 14.8

Adverse events

Collected over Adverse events: For SRD: From the administration of study medication until 7 days, up to day 8. For MRD: From the first administration of study medication until 7 days after the last administration of study medication, i.e. up to 21 days after first drug administration. All-cause mortality: for SRD, up to 9 days, for MRD, up to 28 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Single Dose (SD)0/6 (0%)0/6 (0%)1/6 (16.7%)
Placebo Multiple Dose (MD)0/8 (0%)0/8 (0%)3/8 (37.5%)
BI 1015550 36 milligram (mg) Single Dose (SD)0/6 (0%)0/6 (0%)4/6 (66.7%)
BI 1015550 48 milligram (mg) Single Dose (SD)0/6 (0%)0/6 (0%)4/6 (66.7%)
BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)0/8 (0%)0/8 (0%)2/8 (25%)
BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)0/8 (0%)0/8 (0%)5/8 (62.5%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 milligram (mg) Single Dose (SD)BI 1015550 48 milligram (mg) Single Dose (SD)BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD)BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD)
HeadacheNervous system disorders1/61/81/63/62/83/8
Abdominal distensionGastrointestinal disorders0/61/80/61/60/80/8
Abdominal pain upperGastrointestinal disorders0/60/81/60/60/80/8
ConstipationGastrointestinal disorders0/60/81/60/60/80/8
DiarrhoeaGastrointestinal disorders0/61/81/60/61/80/8
NauseaGastrointestinal disorders1/60/80/60/61/80/8
NasopharyngitisInfections and infestations0/60/80/61/60/80/8
Ligament sprainInjury, poisoning and procedural complications0/60/80/61/60/80/8
Blood creatine phosphokinase increasedInvestigations0/60/81/60/60/80/8
DizzinessNervous system disorders0/60/81/60/60/80/8

Baseline characteristics

Treated set (TS): This subject set included all subjects who had received at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Years)Placebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 Milligram (mg) Single Dose (SD)BI 1015550 48 Milligram (mg) Single Dose (SD)BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD)BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD)Total
Mean34.3 ± 7.933.8 ± 6.632.2 ± 6.638.2 ± 7.935.8 ± 8.733.5 ± 5.334.6 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 Milligram (mg) Single Dose (SD)BI 1015550 48 Milligram (mg) Single Dose (SD)BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD)BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD)Total
Female0000000
Male68668842
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Single Dose (SD)Placebo Multiple Dose (MD)BI 1015550 36 Milligram (mg) Single Dose (SD)BI 1015550 48 Milligram (mg) Single Dose (SD)BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD)BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD)Total
American Indian or Alaska Native0000000
Asian0100001
Native Hawaiian or Other Pacific Islander0000000
Black or African American0110002
White66568839
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jan 2018, 5 months.

Results were first posted in Nov 2025, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 26, 2017
StartActual
Aug 10, 2017
Primary completionActual
Jan 16, 2018
CompletionActual
Jan 16, 2018
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03230487
Responsible party
Sponsor
First posted
Jul 26, 2017
Start date
Aug 10, 2017
Primary completion
Jan 16, 2018
Completion
Jan 16, 2018
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion